CGP 39551 

CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity^[1]. CGP 39551 shows measurable inhibitory activity at both L-[³H]-glutamate (K_i=8.4 μM)^[2].

CGP 39551 inhibits the binding of the selective NMDA receptor antagonist, [³H]-CPP to rat brain postsynaptic densities (PSDs) with a K_i of 310 nM^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CGP 39551 exhibits maximal electroshock-induced seizures in mice with the ED₅₀ of 4 mg/kg (p.o.)^[2].
Following chronic neonatal treatment with CGP 39551, adult rats show increased behavioral responses to the D2 dopamine receptor stimulation^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

237.19

C₈H₁₆NO₅P

127910-32-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. G E Fagg,et al. CGP 37849 and CGP 39551: novel competitive N-methyl-D-aspartate receptor antagonists with potent oral anticonvulsant activity. Prog Clin Biol Res. 1990;361:421-7.  [Content Brief]

  [2]. G E Fagg, et al. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Br J Pharmacol. 1990 Apr;99(4):791-7.  [Content Brief]

  [3]. R Dall'Olio, et al. Chronic neonatal blockade of N-methyl-D-aspartate receptor by CGP 39551 increases dopaminergic function in adult rat. Neuroscience. 1994 Nov;63(2):451-5.  [Content Brief]